IL1A and atopic eczema: Topical treatment regimen consisting of PPARα activator showed potent anti-inflammatory effects in murine models of atopic dermatitis [45, 46] and in irritant and allergic contact dermatitis, which were associated with reduction in pro-inflammatory cytokines TNF-α and IL-1α [47].